SIRT6 and fatty liver disease: In a non-alcoholic fatty liver disease model, USP10 inhibits hepatic steatosis, insulin resistance, and the inflammatory response by interacting with SIRT6 and inhibiting its ubiquitination and degradation (6), and USP10 inhibition also abolishes Mirt2 (long non-coding RNA myocardial infarction associated transcript 2) overexpression-induced suppression of glucose production and lipogenesis in hepatocytes (7).